Is Less More? Rethinking Salvage Therapy in Pediatric Hodgkin Lymphoma

Now, mounting evidence, including findings from three prospective clinical trials, reveal that nontransplant options are an effective second-line treatment for low-risk cHL patients—precluding the need for HDC/ASCT.

Read more: https://consultqd.clevelandclinic.org/is-less-more-rethinking-salvage-therapy-in-pediatric-hodgkin-lymphoma